Cytodyn Inc (CYDY)

[HyGro]

Interesting Dr. Kelly did comparisons on overall survival but he was very deceptive.

Most cancer trials are for relapsed/refractory tumors. Whereas LL was screened for only naive patients -- the easiest to treat. The R/R have already failed on at least two standard of care treatments and are the hard cases.

But Dr. Kelly did his comparison of LL's naive patients to other mTNBC treatments trials for R/R. It is clearly deceptive as he did not even reference that difference that is very significant to the trial outcomes.

More and more Cytodyn misrepresentation. And all while the SEC is already investigating for doing just that!!! But anything to pump the stock.